Kwapisz MM, Kent B, DiQuinzio C, et al. - Researchers used a prospective, randomized and double-blinded design to conduct this study investigating the impact of prophylactic fibrinogen concentrate administration on overall blood product transfusion demands in high-risk cardiac surgery in patients exhibiting low fibrinogen plasma levels. Overall 62 patients undergoing elective, high-risk cardiac surgery were included. Either fibrinogen concentrate or placebo was administered to patients after weaning from cardiopulmonary bypass and reversal of heparin. Overall blood product usage 24 h following intervention was the primary outcome variable. Findings in this cohort examined in a randomized, controlled trial revealed no decrease in the transfusion of blood products in relation to point-of-care guided and prophylactic treatment with fibrinogen concentrate in a setting of unexpectedly low transfusion rate, however, this treatment strategy may improve coagulation parameters in the setting of high-risk cardiac surgery.